Omnicell Inc. (OMCL) Releases Earnings Results, Beats Expectations By $0.06 EPS

Omnicell Inc. (NASDAQ:OMCL) released its earnings results on Thursday. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.32 by $0.06. The company earned $175.60 million during the quarter, compared to analyst estimates of $170.89 million. During the same period in the prior year, the firm posted $0.28 EPS. Omnicell’s revenue was up 55.7% compared to the same quarter last year. Omnicell updated its Q3 guidance to $0.38-0.42 EPS and its FY16 guidance to $1.50-1.60 EPS.

In other Omnicell news, EVP Robin Gene Seim sold 3,645 shares of the company’s stock in a transaction on Friday, July 1st. The shares were sold at an average price of $35.00, for a total transaction of $127,575.00. Following the sale, the executive vice president now owns 55,420 shares of the company’s stock, valued at $1,939,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Dan S. Johnston sold 8,850 shares of the company’s stock in a transaction on Friday, May 20th. The shares were sold at an average price of $30.73, for a total transaction of $271,960.50. Following the sale, the executive vice president now directly owns 73,105 shares in the company, valued at approximately $2,246,516.65. The disclosure for this sale can be found here.

Shares of Omnicell (NASDAQ:OMCL) remained flat at $36.22 during trading on Thursday. The company had a trading volume of 120,164 shares. The stock has a market capitalization of $1.30 billion and a price-to-earnings ratio of 54.47. The company has a 50 day moving average of $34.70 and a 200 day moving average of $30.25. Omnicell has a 12-month low of $25.06 and a 12-month high of $40.01.

A number of research firms recently issued reports on OMCL. Zacks Investment Research raised Omnicell from a “hold” rating to a “strong-buy” rating and set a $41.00 target price on the stock in a research report on Monday, July 11th. FBR & Co lifted their target price on Omnicell from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, July 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $37.25.

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.